The effect of exacerbation history on outcomes in the IMPACT trial

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI in patients with symptomatic COPD and a history of exacerbations. Subgroup analyses assessed whether the efficacy of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Respir J
Main Authors: Halpin, David M.G., Dransfield, Mark T., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lipson, David A., Lomas, David A., Martinez, Fernando J., Pascoe, Steve, Singh, Dave, Wise, Robert, Criner, Gerard J.
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286387/
https://ncbi.nlm.nih.gov/pubmed/32299860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01921-2019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados